Diffuse Pediatric High-grade Glioma of Methylation-based RTK2A and RTK2B Subclasses Present Distinct Radiological and Histomolecular Features Including Gliomatosis Cerebri Phenotype

Diffuse pediatric-type high-grade gliomas (pedHGG), H3- and IDH-wildtype, encompass three main DNA-methylation-based subtypes: pedHGG-MYCN, pedHGG-RTK1A/B/C, and pedHGG-RTK2A/B. Since their first description in 2017 tumors of pedHGG-RTK2A/B have not been comprehensively characterized and clinical correlates remain elusive. In a recent series of pedHGG with a Gliomatosis cerebri (GC) growth pattern, an increased incidence of pedHGG-RTK2A/B (n = 18) was observed. We added 14 epigenetically defined pedHGG-RTK2A/B tumors to this GC series and provided centrally reviewed radiological, histological, and molecular characterization. The final cohort of 32 pedHGG-RTK2A/B tumors consisted of 25 pedHGG-RTK2A (78%) and seven pedHGG-RTK2B (22%) cases. The median age was 11.6 years (range, 4-17) with a median overall survival of 16.0 months (range 10.9-28.2). Seven of 11 of the newly added cases with imaging available showed a GC phenotype at diagnosis or follow-up. PedHGG-RTK2B tumors exhibited frequent bithalamic involvement (6/7, 86%). Central neuropathology review confirmed a diffuse glial neoplasm in all tumors with prominent angiocentric features in both subclasses. Most tumors (24/27 with available data, 89%) diffusely expressed EGFR with focal angiocentric enhancement. PedHGG-RTK2A tumors lacked OLIG2 expression, whereas 43% (3/7) of pedHGG-RTK2B expressed this glial transcription factor. ATRX loss occurred in 3/6 pedHGG-RTK2B samples with available data (50%). DNA sequencing (pedHGG-RTK2A: n = 18, pedHGG-RTK2B: n = 5) found EGFR alterations (15/23, 65%; predominantly point mutations) in both subclasses. Mutations in BCOR (14/18, 78%), SETD2 (7/18, 39%), and the hTERT promoter (7/19, 37%) occurred exclusively in pedHGG-RTK2A tumors, while pedHGG-RTK2B tumors were enriched for TP53 alterations (4/5, 80%). In conclusion, pedHGG-RTK2A/B tumors are characterized by highly diffuse-infiltrating growth patterns and specific radiological and histo-molecular features. By comprehensively characterizing methylation-based tumors, the chance to develop specific and effective therapy concepts for these detrimental tumors increases.

References

Guerrini-Rousseau L, Tauziede-Espariat A, Castel D, Rouleau E, Sievers P, Saffroy R . Pediatric high-grade glioma MYCN is frequently associated with Li-Fraumeni syndrome. Acta Neuropathol Commun. 2023; 11(1):3. PMC: 9817308. DOI: 10.1186/s40478-022-01490-w. View

Sievers P, Sill M, Schrimpf D, Stichel D, Reuss D, Sturm D . A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. Neuro Oncol. 2020; 23(1):34-43. PMC: 7850075. DOI: 10.1093/neuonc/noaa251. View

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

Capper D, Jones D, Sill M, Hovestadt V, Schrimpf D, Sturm D . DNA methylation-based classification of central nervous system tumours. Nature. 2018; 555(7697):469-474. PMC: 6093218. DOI: 10.1038/nature26000. View

Nussbaumer G, Benesch M, Grabovska Y, Mackay A, Castel D, Grill J . Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile. Neuro Oncol. 2024; 26(9):1723-1737. PMC: 11376460. DOI: 10.1093/neuonc/noae080. View

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

Schwartzentruber J, Korshunov A, Liu X, Jones D, Pfaff E, Jacob K . Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012; 482(7384):226-31. DOI: 10.1038/nature10833. View

Mondal G, Lee J, Ravindranathan A, Villanueva-Meyer J, Tran Q, Allen S . Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. Acta Neuropathol. 2020; 139(6):1071-1088. PMC: 7792550. DOI: 10.1007/s00401-020-02155-5. View

Jones C, Karajannis M, Jones D, Kieran M, Monje M, Baker S . Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol. 2016; 19(2):153-161. PMC: 5464243. DOI: 10.1093/neuonc/now101. View

10.

Priesterbach-Ackley L, Boldt H, Petersen J, Bervoets N, Scheie D, Ulhoi B . Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool. Neuropathol Appl Neurobiol. 2020; 46(5):478-492. PMC: 7496466. DOI: 10.1111/nan.12610. View

11.

Korshunov A, Schrimpf D, Ryzhova M, Sturm D, Chavez L, Hovestadt V . H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathol. 2017; 134(3):507-516. DOI: 10.1007/s00401-017-1710-1. View

12.

Jones C, Baker S . Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer. 2014; 14(10). PMC: 4747023. DOI: 10.1038/nrc3811. View

13.

Picart T, Barritault M, Poncet D, Berner L, Izquierdo C, Tabouret E . Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. Neurooncol Adv. 2021; 3(1):vdab061. PMC: 8156974. DOI: 10.1093/noajnl/vdab061. View

14.

Kurokawa R, Baba A, Kurokawa M, Pinarbasi E, Makise N, Ota Y . Neuroimaging features of diffuse hemispheric glioma, H3 G34-mutant: A case series and systematic review. J Neuroimaging. 2021; 32(1):17-27. DOI: 10.1111/jon.12939. View

15.

Tauziede-Espariat A, Debily M, Castel D, Grill J, Puget S, Roux A . Deciphering the genetic and epigenetic landscape of pediatric bithalamic tumors. Brain Pathol. 2021; 32(3):e13039. PMC: 9048515. DOI: 10.1111/bpa.13039. View

16.

Smith H, Collins J, Park D, Darlington W, Quezado M, Aldape K . Pediatric Gliomas Presenting with Gliomatosis-Like Spread, Lack of Contrast Enhancement, EGFR Mutation, and TERT Promoter Variants. J Neuropathol Exp Neurol. 2021; 80(12):1134-1136. PMC: 8851669. DOI: 10.1093/jnen/nlab093. View